Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 34c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 34c, Revenues Miss

Eagle Pharmaceuticals Reports Second Quarter 2020 Results

August 10, 2020 6:50 AM EDT

-- Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share --

-- Anticipate launch of vasopressin, maintaining our 180-day market exclusivity --

-- CMS establishes unique J-code for PEMFEXY (pemetrexed for injection); FDA granted supplement approval for 500mg multiple-dose vial --

-- Received positive additional data for the Companys fulvestrant product candidate, EA-114, for HR-positive advanced breast cancer --

-- Received a Complete Response Letter for NDA for... More